ARTICLE | Finance
Cost averaging down
4Q biotech stock preview: Investors looking to find good bargains
October 3, 2011 7:00 AM UTC
Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead are using price weakness to strengthen portfolios.
Some are focusing mainly on clinical milestones, given the unpredictability of the launch landscape. But others are picking over beaten-up launch stories even though they expect generalist investors will think twice about plunging back into biotech after the thrashing they took in new commercialization stories like Dendreon Corp...